Last updated on February 2018

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions


Brief description of study

This is a non interventional prospective study. Centers will enroll adult participants with partial onset seizures with or without secondary generalisation for whom the clinician has decided to initiate ESL as an adjunctive therapy prior to the decision to take part in this study. Participants to be enrolled into the study will receive eslicarbazepine acetate (ESL) either as an adjunctive therapy to one baseline antiepileptic drug (AED) or to at least two baseline AEDs. Participants will be seen at baseline and at a follow-up visit after approximately 6 months to assess retention, efficacy, tolerability, quality of life (optional), and cognitive performances (optional).

Clinical Study Identifier: NCT03082222

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.